'multiple sclerosis' posts

The MS Center at Swedish Neuroscience Institute will present the MS Roadshow April 26 in Mt. Vernon, Washington. The MS Roadshow is a free, half-day educational workshop about living well with multiple sclerosis (MS).

Knowledge really is power when it comes to managing your health. For people living with MS, learning as much as possible about the disease makes it easier to make informed decisions about your care.

Whether newly diagnosed or looking for more information to help improve your health, the MS Roadshow offers a look at leading-edge research and tips for living a full life. Topics and speakers include:

On March 27, the U.S. Food and Drug Administration approved the newest treatment in the increasing number of disease modifying therapies (DMTs) available to treat multiple sclerosis. Tecfidera (BG-12) is an oral capsule to treat adults with relapsing forms of MS. Research participants at the MS Center at Swedish participated in clinical trials for Tecfidera.

The trials reported that people taking Tecfidera had fewer relapses and less frequent worsening of disability compared to people taking a placebo. There were also fewer and less-severe side effects with Tecfidera than other treatments.

The studies found that ...

Every hour, someone is diagnosed with multiple sclerosis (MS). And every day, people from around the Pacific Northwest and United States visit the MS Center at Swedish to learn how to live well with the disease.

Multiple sclerosis is a disease of the nervous system that affects the brain, eyes and spinal cord that takes a unique course in every patient. We’re with people on their journey, whether they are newly diagnosed or have been living with MS for decades. Patients and families share their lives with our treatment team and, in turn, we put our passion into helping them achieve their highest wellbeing.

Participating in Walk MS one way we show our commitment to caring for the MS community.

Neurologists and neuroscience professionals this week from around the world gathered at the American Academy of Neurology (AAN) 65th Annual Meeting in San Diego. The Multiple Sclerosis Center at Swedish Neuroscience Institute was pleased to co-author a few research trials presented at the meeting:

Teriflunomide and pregnancy

Dr. Lily Jung-Henson, neurologist and Chief of Staff at Swedish Issaquah, spoke on behalf of a team of researchers about teriflunomide and a report on the safety of women who became pregnant on the medication. Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) recently approved in the United States to treat relapsing multiple sclerosis. Clinical trials for teriflunomide took place among the many research studies for new treatments Swedish Neuroscience Institute offers patients with multiple sclerosis. (Read the full abstract here.)

Subset of a trial looking at endurance effects of Dalfampridine (AMPYRA®)

Dr. Angeli Mayadev, physical medicine and rehabilitation specialist at the MS Center, participated in this study of a medication to improve walking speed in people with MS. Dalfampridine -ER 10 mg twice daily significantly improved 6-minute walking distance compared to placebo. Dalfampridine 5 mg twice daily did not improve distance compared to placebo. Researchers also found that ....

A small pilot study from the University of Southern California suggests a pulse adrenocorticotropic hormone (ACTH) therapy could be effective in patients with breakthrough multiple sclerosis attacks while on beta-interferon. “Breakthrough” attacks that occur after starting a disease modifying therapy (DMT).

The study compared the safety and benefits of monthly pulse ACTH to monthly methylprednisone (MP) pulse in patients on beta-interferon. Over 15 months, researchers found that those treated with ACTH had fewer relapses and fewer psychiatric side effects. ACTH gel is currently used to treat MS relapses, but researchers note it may be able to alter the body’s immune responses beyond producing steroids.

As I discussed with the Medscape reporter, Megan Brooks, last week, the results of this study are ....

Dr. James Bowen appeared today with Ryan Asdourian, “the man behind the bird” and Seahawks’ mascot Blitz, on the Seattle talk show New Day Northwest to shed some light on common misconceptions about multiple sclerosis (MS).

Host Margaret Larson asked Dr. Bowen about myths about MS as part of the program to promote this year’s Walk MS events in Seattle. Ryan Asdourian is proof of the full life many people lead with MS, rallying fans at Seahawks games and raising MS awareness as an active advocate for the National Multiple Sclerosis Society.

You can check out the video from KING5 TV’s website below. Find out more about how to join or donate to the Swedish S’myelin Strider’s Walk MS team at www.swedish.org/MS.

Increased dietary salt was reported to increase the immune attack on myelin in three studies this week. All three were published in the journal Nature.

1. A study by Kleinewietfeld, et al, looked at TH17 cells, which is a type of lymphocyte that is highly inflammatory and that causes substantial tissue damage. These cells were grown in cultures in the lab. Some had normal and others high salt levels in their cultures. Those grown in a high salt environment had increased markers for inflammation. This seemed to be due to activation of one particular set of chemical signals in the cell, called the p38/MAPK pathway. They also looked at mice with an MS-like disease called experimental allergic encephalomyelitis (EAE). Mice fed a high salt diet had worse EAE than those fed a normal diet.
2. A study by Wu, et al, also looked at TH17 cells. An analysis was done on genes associated with activation of TH17 cells, and SGK1 was identified as an important protein in this process. The SGK1 pathway was found to be more active if cells were cultured in a high salt environment. This was then studied in mice with EAE. Mice fed a high salt diet had more severe EAE. Blocking the SGK1 pathway seemed to reverse the effect of the high salt diet on the EAE.
3. A study by Yosef, et al, also looked a the genes associated with activation of TH17 cells. They identified 22 sets of related genes that increased TH17 cell activity and 5 that decreased activity.

TH17 cells are highly inflammatory and likely contribute to the severe damage done to tissues in a number of diseases. Their precise role in MS is not fully understood, but it is believed that ...